# A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

Study · id `cardio:ct-nct03496207` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03496207](<https://clinicaltrials.gov/study/NCT03496207>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03496207

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

## Technical summary

Registry record NCT03496207. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-13 (actual); primary completion 2022-03-09 (actual). Results posted on 2023-04-19.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 106 participants (enrolled count; ClinicalTrials.gov record NCT03496207, source copy `cardio:ctgov-nct03496207-2023-04-19`, retrieved 2026-10-31)
- Started: 2018-06-13 (actual) (ClinicalTrials.gov record NCT03496207, source copy `cardio:ctgov-nct03496207-2023-04-19`, retrieved 2026-10-31)
- Primary completion: 2022-03-09 (actual) (ClinicalTrials.gov record NCT03496207, source copy `cardio:ctgov-nct03496207-2023-04-19`, retrieved 2026-10-31)
- Completion: 2022-03-09 (actual) (ClinicalTrials.gov record NCT03496207, source copy `cardio:ctgov-nct03496207-2023-04-19`, retrieved 2026-10-31)
- Results first posted: 2023-04-19 (ClinicalTrials.gov record NCT03496207, source copy `cardio:ctgov-nct03496207-2023-04-19`, retrieved 2026-10-31)
- Countries: United States; Australia; Brazil; France; Germany; Israel; Spain; United Kingdom (ClinicalTrials.gov record NCT03496207, source copy `cardio:ctgov-nct03496207-2023-04-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03496207-2023-04-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
- Acronym: PULSAR
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Placebo
- Intervention (Drug): Sotatercept
- Intervention (Other): SOC
- Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (`cardio:org-acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-co-341e98`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension (`cardio:pubmed-36041750`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR) (`cardio:pubmed-40035659`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ac34c0b5f4c1a0ab79732dcc5300c17d28a87a06eb2932464160645b6c3391ec
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
